Randall Urban, MD
Vice President for Research &
Chief Research Officer

Dr. Randall Urban

Dr. Randall Urban leads a diverse research community in the bold mission to improve medical practice through progressive translational research endeavors. He has 145 peer-review publications, is the Principal Investigator of UTMB's Clinical and Translational Science Award, and has 3 major research interests funded by the NIH and private foundations. In addition to Vice President for Research and Chief Research Officer, Dr. Urban is Vice Dean for Clinical Research in the John Sealy School of Medicine, Professor of Internal Medicine, Director of the Institute for Translational Sciences, and Fellow, John P. McGovern Distinguished Chair in Oslerian Medicine.

Strategic Research Plan

The Strategic Research Plan, which is used by leadership to  develop a path forward through goals, objectives and tactics, has broad input. It includes six integrated health communities that bring together researchers, educators, clinicians and community members to use prevention and treatment to transform illness to health. Read more.

Research Funding
Awards Processed
Lab Space
See more research facts and figures online





Research uncovers possible monoclonal antibody treatment for Lassa fever

New research out of the University of Texas Medical Branch potentially points to an effective treatment for Lassa fever, a dangerous, often fatal disease common to much of West Africa but considered a major threat to global health.

In a paper published in the journal Proceedings of the National Academy of Sciences, UTMB’s scientists document how a new drug from Zalgen Labs successfully cured cynomolgus monkeys infected with Lassa virus.

There currently is no approved treatment for the disease, which is estimated to infect 300,000 to 500,000 people a year across the region and cause at least 5,000 deaths annually.

Women and children are at the highest risk from Lassa fever, which is characterized by bleeding and coagulation abnormalities, with overall mortality rates exceeding 25 percent and reaching 50 percent during epidemics.

Exposure to infected animals is the most common cause of infection in humans. A recent study that identified the top 50 agents with pandemic potential, Lassa fever was ranked first among known viruses regarded as a threat for zoonotic spillover.

Though less common, human-to-human transmission is caused through exposure to blood or secretions and through sexual contact.

Those in the early stages of the disease often show mild or no symptoms and therefore tend not to seek help until their condition is advanced. About 20 percent of patients progress to viral hemorrhagic fever.

“Lassa virus has a high level of genetic diversity across much of West Africa,” said Dr. Robert Cross, associate professor in the Department of Microbiology & Immunology and one of the authors of the study. “This creates a real challenge for therapeutic developers as it raises the question of whether a single drug could be used to treat all Lassa virus infections.”

The UTMB research shows the potential of Zalgen Labs’ Arevirumab-3 therapeutic, a monoclonal antibody cocktail, as a treatment against all major strains of the disease in advanced stages.

The study concluded that the Arevirumab-3 therapeutic successfully treated cynomolgus monkeys when administered beginning at advanced stages of disease caused by two different major strains of Lassa virus that were involved in the research.

The results indicated Arevirumab-3 potentially could be used to treat humans infected with Lassa virus.

Arevirumab-3 is on a path toward Investigational New Drug status with the U.S. Food and Drug Administration and toward projected Phase 1 clinical studies to assess its safety and efficacy in healthy human subjects. 

“This study represents yet another proof that broad protective treatments, here against the highly complex and variable hemorrhagic fever Lassa virus, can be developed with cutting-edge research within secure high-containment laboratory environments,” said Dr. Gary Kobinger, director of the Galveston National Laboratory.

The finding is the result of an ongoing research collaboration between UTMB, Zalgen and Tulane University. UTMB, along with Tulane, is conducting additional studies to further explore the use of Arevirumab-3 against divergent and emerging strains.

“This work is yet another example of our dedication of UTMB and its many collaborative partners, including Zalgen Labs and Tulane University, to refine monoclonal antibody therapies against Lassa virus.” Cross said. ‘It no doubt will serve as further support of the value of continued investment in immunotherapeutics research for the treatment of Lassa fever in humans.”